Literature DB >> 11856351

Concentration-dependent reversible activation-inhibition of human butyrylcholinesterase by tetraethylammonium ion.

Jure Stojan1, Marko Golicnik, Marie-Thérèse Froment, Francois Estour, Patrick Masson.   

Abstract

Tetraalkylammonium (TAA) salts are well known reversible inhibitors of cholinesterases. However, at concentrations around 10 mm, they have been found to activate the hydrolysis of positively charged substrates, catalyzed by wild-type human butyrylcholinesterase (EC 3.1.1.8) [Erdoes, E.G., Foldes, F.F., Zsigmond, E.K., Baart, N. & Zwartz, J.A. (1958) Science 128, 92]. The present study was undertaken to determine whether the peripheral anionic site (PAS) of human BuChE (Y332, D70) and/or the catalytic substrate binding site (CS) (W82, A328) are involved in this phenomenon. For this purpose, the kinetics of butyrylthiocholine (BTC) hydrolysis by wild-type human BuChE, by selected mutants and by horse BuChE was carried out at 25 degreeC and pH 7.0 in the presence of tetraethylammonium (TEA). It appears that human enzymes with more intact structure of the PAS show more prominent activation phenomenon. The following explanation has been put forward: TEA competes with the substrate at the peripheral site thus inhibiting the substrate hydrolysis at the CS. As the inhibition by TEA is less effective than the substrate inhibition itself, it mimics activation. At the concentrations around 40 mm, well within the range of TEA competition at both substrate binding sites, it lowers the activity of all tested enzymes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11856351     DOI: 10.1046/j.1432-1033.2002.02749.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  6 in total

1.  Homocysteine thiolactone and human cholinesterases.

Authors:  Sultan Darvesh; Ryan Walsh; Earl Martin
Journal:  Cell Mol Neurobiol       Date:  2006-09-06       Impact factor: 5.046

2.  Kinetically-controlled mechanism-based isolation of metabolic serine hydrolases in active form from complex proteomes: butyrylcholinesterase as a case study.

Authors:  Hui Liu; Huimin Zhou; Huaqiao Du; Qiaoling Xiao; Marco Pistolozzi
Journal:  RSC Adv       Date:  2019-11-26       Impact factor: 4.036

3.  An evaluation of the inhibition of human butyrylcholinesterase and acetylcholinesterase by the organophosphate chlorpyrifos oxon.

Authors:  Josephine Shenouda; Paula Green; Lester Sultatos
Journal:  Toxicol Appl Pharmacol       Date:  2009-08-19       Impact factor: 4.219

4.  Development of an in-vivo active reversible butyrylcholinesterase inhibitor.

Authors:  Urban Košak; Boris Brus; Damijan Knez; Roman Šink; Simon Žakelj; Jurij Trontelj; Anja Pišlar; Jasna Šlenc; Martina Gobec; Marko Živin; Larisa Tratnjek; Martina Perše; Kinga Sałat; Adrian Podkowa; Barbara Filipek; Florian Nachon; Xavier Brazzolotto; Anna Więckowska; Barbara Malawska; Jure Stojan; Irena Mlinarič Raščan; Janko Kos; Nicolas Coquelle; Jacques-Philippe Colletier; Stanislav Gobec
Journal:  Sci Rep       Date:  2016-12-21       Impact factor: 4.379

5.  Rapid Mechanistic Evaluation and Parameter Estimation of Putative Inhibitors in a Single-Step Progress-Curve Analysis: The Case of Horse Butyrylcholinesterase.

Authors:  Jure Stojan
Journal:  Molecules       Date:  2017-07-26       Impact factor: 4.411

6.  Identification of Compounds for Butyrylcholinesterase Inhibition.

Authors:  Shuaizhang Li; Andrew J Li; Jameson Travers; Tuan Xu; Srilatha Sakamuru; Carleen Klumpp-Thomas; Ruili Huang; Menghang Xia
Journal:  SLAS Discov       Date:  2021-07-16       Impact factor: 3.341

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.